FREE Account Opening + No Clearing Fees
Loading...

Gland Pharma IPO vs IRFC IPO

Comparision between Gland Pharma IPO and IRFC IPO.

IPO Details

Gland Pharma IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while IRFC IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.

Issue Size and Price

The total issue size of Gland Pharma IPO is up to ₹6,479.55 Cr whereas the issue size of the IRFC IPO is up to ₹4,633.38 Cr. The final issue price of Gland Pharma IPO is ₹1,500.00 per share and of IRFC IPO is ₹26.00 per share.

  Gland Pharma IPO IRFC IPO
Face Value ₹1 per share ₹10 per share
Issue Price (Lower) ₹1,490.00 per share ₹25.00 per share
Issue Price (Upper) ₹1,500.00 per share ₹26.00 per share
Issue Price (Final) ₹1,500.00 per share ₹26.00 per share
Discount (Retail)
Discount (Employee)
Market Lot Size 10 shares 575 shares
Fresh Issue Size 83,33,333 shares 1,18,80,46,000 shares
Fresh Issue Size (Amount) up to ₹1,250.00 Cr
OFS Issue Size 3,48,63,635 shares 59,40,23,000 shares
OFS Issue Size (Amount) up to ₹5,229.55 Cr
Issue Size Total 4,31,96,968 shares 1,78,20,69,000 shares
Issue Size Total (Amount) up to ₹6,479.55 Cr up to ₹4,633.38 Cr

IPO Timetable

Gland Pharma IPO opens on Nov 09, 2020, while IRFC IPO opens on Jan 18, 2021. The closing date of Gland Pharma IPO and IRFC IPO is Nov 11, 2020, and Jan 20, 2021, respectively.

  Gland Pharma IPO IRFC IPO
Anchor Bid Date
Issue Open Nov 09, 2020 Jan 18, 2021
Issue Close Nov 11, 2020 Jan 20, 2021
Basis Of Allotment (Tentative) Nov 17, 2020 Jan 25, 2021
Initiation of Refunds (Tentative) Nov 18, 2020 Jan 27, 2021
Credit of Share (Tentative) Nov 19, 2020 Jan 28, 2021
Listing date (Tentative) Nov 20, 2020 Jan 29, 2021
Anchor Lockin End date 1 Dec 17, 2020 Feb 24, 2021
Anchor Lockin End date 2 Feb 15, 2021 Apr 25, 2021

Financials

Gland Pharma IPO P/E ratio is , as compared to IRFC IPO P/E ratio of .

  Gland Pharma IPO IRFC IPO
Financial
Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (Rs in million)
30-June-20 31-Mar-20 31-Mar-19 31-Mar-18
Total Assets 46,912.65 40,860.39 35,235.49 29,294.68
Total Revenue 9,162.89 27,724.08 21,297.67 16,716.82
Profit After Tax 3,135.90 7,728.58 4,518.56 3,210.51
Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (Rs in million)
30-Sep-20 31-Mar-20 31-Mar-19 31-Mar-18
Total Assets 29,19,865.81 27,55,041.29 20,64,382.95 16,14,510.41
Total Revenue 73,848.29 1,34,210.90 1,09,873.55 92,078.39
Profit After Tax 18,868.41 31,920.96 21,399.33 20,014.60
Promoter Shareholding (Pre-Issue) 74% 100%
Promoter Shareholding (Post-Issue) 58% 86%
P/E Ratio
Market Cap
ROE
ROCE
Debt/Equity
EPS
RoNW

Shares Offered

In the Gland Pharma IPO retail investors (RII) are offered 1,51,18,939 shares while in IRFC IPO retail investors are offered 1,51,18,939 shares. Qualified institutional buyers (QIB) are offered 86,39,394 shares in Gland Pharma IPO and 35,63,75,339 shares in IRFC IPO.

  Gland Pharma IPO IRFC IPO
Anchor Investor Reserveration
Market Maker Reserveration
QIB 86,39,394 shares 35,63,75,339 shares
NII 64,79,546 shares 26,72,81,504 shares
RII 1,51,18,939 shares 62,36,56,843 shares
Employee 0 shares 1,92,307 shares
Others
Total 3,02,37,879 shares 1,24,75,05,993 shares

Bids Received (Subscription)

Gland Pharma IPO subscribed 2.06x in total, whereas IRFC IPO subscribed 3.49x.

  Gland Pharma IPO IRFC IPO
QIB (times) 6.40x 3.78x
NII (times) 0.51x 2.67x
Big NII (times)
Small NII (times)
RII (times) 0.24x 3.66x
Employee (times) 43.76x
Other (times)
Total (times) 2.06x 3.49x

Comments

Add a public comment...